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ABSTRACT 
 
Prognosis of basal breast cancers is poor but heterogeneous. Medullary 
breast cancers (MBC) display a basal profile, but a favorable prognosis. W e 
hypothesized that a previously published 368-gene expression signature associated 
with MBC might serve to define a prognostic classifier in basal cancers. We collected 
public gene expression and histoclinical data of 2145 invasive early breast 
adenocarcinomas. We developed a Support Vector Machine (SVM) classifier based 
on this 368-gene list in a learning set, and tested its predictive performances in an 
independent validation set. Then, we assessed its prognostic value and that of six 
prognostic signatures for disease-free survival (DFS) in the remaining 2034 samples. 
The SVM model accurately classified all MBC samples in the learning and validation 
sets. A total of 466 cases were basal across other sets. The SVM classifier separated 
them into two subgroups, subgroup 1 (resembling MBC) and subgroup 2 (not 
resembling MBC). Subgroup 1 exhibited 71% 5-year DFS, whereas subgroup 2 
exhibited 50% (p=9.93E-05). The classifier outperformed the classical prognostic 
variables in multivariate analysis, conferring lesser risk for relapse in subgroup 1 
(HR=0.52, p=3.9E-04). This prognostic value was specific to the basal subtype, in 
which none of the other prognostic signatures was informative. Ontology analysis 
revealed effective immune response, enhanced tumor cell apoptosis, elevated levels 
of metastasis-inhibiting factors and low levels of metastasis-promoting factors in the 
good-prognosis subgroup, and a more developed cell migration system in the poor-
prognosis subgroup. In conclusion, based on this 368-gene SVM model derived from 
an MBC signature, basal breast cancers were classified in two prognostic subgroups, 
suggesting that MBC and basal breast cancers share similar molecular alterations 
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associated with aggressiveness. This signature could help define the prognosis, 
adapt the systemic treatment, and identify new therapeutic targets. 
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INTRODUCTION 
Prognosis of breast cancer is heterogeneous and imperfectly captured by 
classical histoclinical features, making clinical evolution difficult to predict for a given 
patient and treatment not perfectly adapted. Over the past decade [1], gene 
expression profiling revealed five molecular subtypes of breast cancer based on the 
expression patterns of an intrinsic gene set: luminal A and B, basal, ERBB2 and 
normal-like [2]. These subtypes represent different disease entities associated with 
specific molecular alterations and histoclinical features [3-7]. This classification 
correlates with major prognostic variables. Thus, its added prognostic value remains 
unclear. However, it provides the opportunity to investigate biological questions, such 
as the identification of prognostic or therapeutic targets, in more homogenous entities, 
and therefore enrich for a signal relevant in a specific subtype, which would be 
diluted and undetectable in the whole breast cancer population [8]. For example, the 
predictive value of P53 mutations regarding the response to chemotherapy is 
opposite according to luminal A or basal subtype [9]. In a recent meta-analysis [10], 
similar observations were done with seven prognostic multigene expression 
signatures [11-18], which were highly informative of clinical outcome in ER+/ERBB2- 
cases, but much less informative and never significant in ER-/ERBB2- and ERBB2+ 
cases. One of the reason is that three of the four signatures defined by supervised 
analysis had been initially defined in ER+ tumors [13,15], or by separately analyzing 
ER+ and ER- tumors but with a few ER- cases and without taking into account the 
heterogeneity of ER- tumors [17]. Few studies have attempted to derive prognostic 
signatures of ER- breast cancer [19-22], and all showed the difficulty of the task.  
The basal subtype represents around 15% of invasive breast cancers. Most 
basal breast cancers are of ductal type [23]. Despite a relative chemosensitivity when 
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compared to other subtypes they display a poor prognosis after treatment, which 
generally includes adjuvant chemotherapy. However, this subtype shows prognostic 
heterogeneity since not all basal breast cancer patients have an unfavorable 
outcome. To date, reliable identification of basal breast cancer patients with a good 
or a poor prognosis is difficult and based only on histological features thus far from 
optimal [24,25]. If optimized, this would help tailor treatment by using more or less 
aggressive approaches based on the prediction of outcome, all the more so as 
different types of chemotherapy are available, and promising targeted molecular 
therapies are under development for these tumors [26,27]. Furthermore, such 
optimization, if based on molecular data, should help identify new potential 
therapeutic targets. 
Medullary breast cancers (MBC) represent less than 2% of breast cancers. 
Despite features of aggressiveness and the fact that they frequently display a basal 
profile [28,29], MBC are associated with a favorable prognosis. Using whole-genome 
oligonucleotide microarrays, we recently reported a list of 368 genes differentially 
expressed between basal MBC and nonMBC. Here, we used MBC as a model of 
good-prognosis basal breast cancer and tested the hypothesis that this gene 
signature might be used to derive a gene classifier predictive for disease-free survival 
(DFS) in a large pooled data set of basal breast cancers. 
 
 
MATERIALS AND METHODS  
 
Tumor samples 
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We collected personal and public data from breast cancer samples profiled 
using DNA microarrays. Inclusion criteria included: pre-treatment sample of an 
invasive adenocarcinoma, non-inflammatory and non-metastatic, with available 
histoclinical data, and profiled using Affymetrix or Agilent oligonucleotide microarrays. 
All data sets were retrospective. They are described in Supplementary Table 1. The 
Weigelt‟s set [30] was used to validate the MBC-nonMBC SVM classifier. Other sets 
(thereafter designated “prognostic series”) were pooled to test the prognostic impact 
of this classifier in basal breast cancers and other subtypes; they included our series 
(Institut Paoli-Calmettes – IPC) and 15 public series. The IPC series contained frozen 
tumor samples obtained from 266 early breast cancer patients who underwent initial 
surgery in our institution between 1992 and 2004. They included 227 cases 
previously reported [31] and 39 additional cases, all similarly profiled using Affymetrix 
U133 Plus 2.0 human oligonucleotide microarrays as previously described [31]. The 
study was approved by the IPC review board, and informed consent was available for 
each case. This IPC series did not include the 37 cases from which we had derived 
the 368-gene list. The 15 public series originated from 15 publications [11-13,17,32-
42]. Overall, data from a total of 3409 patient‟s samples were collected. When 
different publications included the same patients, the redundancy was eliminated, 
resulting in 2145 different patient‟s samples (111 in the Weigelt‟s set and 2034 in the 
“prognostic series”). Gene expression and histoclinical data of public series were 
retrieved from NCBI GEO databases and authors‟ website. Histoclinical data of our 
IPC series are available in Supplementary Table 2. 
 
Gene expression data pre-processing 
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Before analysis, we mapped hybridization probes across the two technological 
oligonucleotide-based platforms (Agilent and Affymetrix) used across the series. 
Affymetrix gene chips annotations were updated using NetAffx Annotation files 
(www.affymetrix.com; release from 01/12/2008). Agilent gene chips annotations were 
retrieved and updated using both SOURCE (http://smd.stanford.edu/cgi-
bin/source/sourceSearch) and EntrezGene (Homo sapiens gene information db, 
release from 09/12/2008, ftp://ftp.ncbi.nlm.nih.gov/gene/). All probes were thus 
mapped based on their EntrezGeneID. When multiple probes were mapped to the 
same GeneID, the one with the highest variance in a particular dataset was selected 
to represent the GeneID.  
Data sets were then processed as follows. For the Agilent-based sets, we 
applied quantile normalization to available processed data. Regarding the Affymetrix-
based data sets, we used Robust Multichip Average (RMA) [43] with the non-
parametric quantile algorithm as normalization parameter. RMA was applied to the 
raw data from the other series and the IPC series. Quantile normalization or RMA 
was done in R using Bioconductor and associated packages. 
 
Gene expression data analysis 
Analysis of each processed data set was done separately to guarantee a 
larger number of genes common with the intrinsic gene set, the 368-gene list, and the 
published prognostic signatures. 
The molecular subtypes related to the intrinsic breast cancer classification 
were determined using Hu‟s Single Sample Predictor (SSP) classifier based on a list 
of 306 intrinsic genes [35]. We first identified the genes common between the intrinsic 
gene set and each expression data set. We then used Distance Weighted 
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Discrimination (DWD) [44] to normalize each data set in order to be comparable to 
the 315 samples of the Hu‟s combined test sample set. Next, we defined the 
expression centroid of each subtype for the common probe sets in this combined test 
sample set [35]. Finally, we measured the correlation of each sample with each 
centroid. The sample was attributed the subtype corresponding to the most 
correlated centroid.  
Before constructing our classifier based on the 368-gene list and testing its 
performances, as well as those of other prognostic signatures, in several 
independent data sets, gene expression levels of each data set were standardized 
using the luminal A population as reference, thus allowing to make comparable all 
data sets. In a previous study [28], we had identified 534 probe sets differentially 
expressed between basal MBC and basal nonMBC. They represented 368 unique 
genes. We hypothesized that some nonMBC might have an expression profile close 
to that of MBC for these genes, and perhaps better prognosis than other nonMBC. 
Based on this 368-gene list (Supplementary Table 3), we defined a genomic classifier 
using Support Vector Machine (SVM). The initial outcome of interest for this SVM 
classifier was the separation MBC-nonMBC, with the secondary objective, in the case 
where all nonMBC would not be correctly classified, to compare the clinical outcome 
of these two nonMBC subgroups. Briefly, the SVM algorithm finds in the learning set 
the hyperplane separating the two subgroups with maximized margins in Euclidean 
space. This approach allows separation by mapping the data into a high-dimensional 
feature space that can be linearly separated via a kernel function. Once trained, the 
classification only requires the linear computation using the learned hyperplane 
equation. The resulting SVM classification score defines the distance from the 
hyperplane and so the membership to one of the two subgroups First, we established 
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the SVM model in our original 37-sample data set (learning set: 16 basal nonMBC 
and 21 basal MBC) [28], with a polynomial kernel of degree 3. This model classified 
samples in two subgroups (1 and 2). To test the stability of the SVM model according 
to the composition of the learning set, we applied 100 random subsamplings to the 
37 sample-set by splitting it into training (two thirds of samples) and validation data 
(remaining one third). For each iteration, the predictive accuracy of the model fitted to 
the training data was assessed using the validation data, and the results were then 
averaged over the 100 splits. After having identified the genes common between the 
368-gene list and each data set, the SVM model was applied within each set, notably 
the Weigelt‟s independent validation set, to attribute each sample to subgroup 1 or 2.  
For comparison with our classifier, we tested the predictive value of six major 
recently reported prognostic breast cancer signatures: the 70-gene signature [11,12], 
the 76-gene signature [17], the invasiveness gene signature [18], the wound 
response signature [14], the genomic grade index [13], and the 21-gene recurrence 
score [15]. Each signature was applied to each expression data set separately to 
compute a relapse risk to each sample. We first identified the genes common 
between the signature and each data set. We then strictly applied the same 
methodology (score or Pearson correlation, and scaling methods) as that reported in 
the original publications to classify each sample. The original cut-off then defined the 
membership to the predicted good-prognosis group or the predicted poor-prognosis 
group. More details are available in Supplementary Table 4. 
The 368-gene list was interrogated using Ingenuity software (Redwood City, 
CA, USA) to assess significant representation of biological pathways 
 
Statistical analysis 
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Correlations between sample groups and histoclinical factors were calculated 
with the Fisher‟s exact test for qualitative variables with discrete categories, and the 
Mann-Whitney test for continuous variables. Disease-free survival (DFS) was 
calculated from the date of diagnosis until date of first relapse whatever its location 
(local, regional or distant) or date of death (when the relapse data was not available) 
using the Kaplan-Meier method. Survival was compared between groups with the 
log-rank test. Follow-up was measured from the date of diagnosis to the date of last 
news for patients without any event. In the “prognostic series” (2034 patients), follow-
up was available for 1752 patients (median 88 months) and the 5-year DFS was 
68%. Univariate and multivariate analyses were done using Cox regression analysis. 
The variables tested in univariate analyses included age of patients, pathological 
tumor size, axillary lymph node status, and SBR grade, ER, PR, ERBB2, and Ki67 
IHC status, our SVM model and several published prognostic multigene signatures. 
Multivariate analysis was done by incorporating all variables with a p-value inferior to 
0.05 in univariate analysis. The p-values were based on the Wald test, and patients 
with one or more missing data regarding the retained variables were excluded. All 
statistical tests were two-sided at the 5% level of significance. Statistical analysis was 
done using the survival package (version 2.30), in the R software (version 2.9.1). 
 
 
RESULTS  
 
Intrinsic molecular subtypes 
We collected publicly available gene expression and histoclinical data of a 
total of 2145 distinct invasive breast adenocarcinomas. We determined the molecular 
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subtype of tumors in each data set separately by using the SSP method [35]. The 
percent of genes common to each set and the intrinsic 306-gene set ranged from 88 
to 100%.  
In the Weigelt‟s series [30], which contained 10 MBC and 101 non-MBC, 32 
tumors were determined as basal. As previously reported by us and others [28,29], 
all 10 MBC were basal subtype. In this series, only the pathological type was 
available. 
In the “prognostic series” (2034 samples), available histoclinical data allowed 
us to verify the coherence of the subtypes, notably the basal subtype, in term of 
histoclinical correlations (Table 1). As expected, basal tumors (466 cases) were 
diagnosed in younger patients when compared with luminal A tumors. They were 
also more frequently ductal, with higher pathological size and grade; they were more 
frequently negative for ER and PR as defined by immunohistochemistry (IHC), but 
more often positive for P53 and Ki67. Clinical outcome, available for 1752 patients, 
strongly correlated with subtypes with 5-year DFS of 80% for luminal A (149 events), 
57% for luminal B (152 events), 72% for normal-like (78 events), 60% for basal (157 
events), and 60% for ERBB2+ (107 events). These results, obtained in a large series 
of samples, confirmed previous observations, and the coherence of our data set.  
 
The 368-gene model defines two subgroups of basal breast cancers 
We used the 37 IPC samples (16 nonMBC and 21 MBC) from which we had 
generated the 368-gene signature to construct a SVM classifier. As expected, its 
application onto this learning set resulted in a correct classification of all MBC  in 
subgroup 1 and 14 out of 16 nonMBC in subgroup 2  (Figure 1A). By cross-validation 
using 100 random iterations, the mean predictive accuracy was 73% (95%CI, [69 – 
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76]), suggesting the robustness of our SVM model. Its robustness was further tested 
in an independent public data set [30], which included 10 MBC and 101 nonMBC, of 
which 32 were basal. The SVM model applied to these 32 tumors (Figure 1B) 
correctly classified all 10 MBC samples in subgroup 1, whereas 10 out of 22 nonMBC 
were classified in subgroup 2 and 12 in subgroup 1. This observation suggested that 
the model is very sensitive for MBC prediction, and that basal nonMBC are 
heterogeneous regarding the model, with some cases (subgroup 1) resembling more 
than other cases (subgroup 2) to MBC. This confirmed our initial hypothesis and 
allowed us to compare the prognosis of these two nonMBC subgroups. 
Finally, to test for a prognostic value of such subgrouping, the SVM classifier 
was applied to each public series separately. The percent of genes common between 
the 368-gene list and each data set ranged from 72 to 100%. In each set, two tumor 
subgroups were obtained. Among the 466 pooled basal samples, 217 samples were 
in subgroup 1 and 249 in subgroup 2 (Figure 2A).  
 
Histoclinical features and prognosis of the two basal subgroups 
We compared the histoclinical features of the two subgroups of basal tumors 
defined by the SVM classifier (Table 2). Out of the nine tested variables, differences 
(Fisher‟s exact test) were observed only for age of patients and ER status, with 
younger patients (p=4.95E-03) and more ER- cases (p=9.14E-04) in subgroup 1. 
There was no significant difference regarding pathological tumor size, axillary lymph 
node status, grade, and IHC status for PR, ERBB2, P53 and KI67. Survival 
information was available for 392 of 466 patients. The survival curves are shown in 
Figure 2B. With a median follow-up of 81 months, 5-year DFS was better - despite a 
longer follow-up - for subgroup 1 patients (71% DFS) than for subgroup 2 patients 
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(50% DFS, p=9.93E-05, log-rank test). Analysis by data set showed that the mean 
difference of 5-year DFS between subgroups 1 and 2 was 17% (95%CI, [4 – 30], 
p=0.016). For comparison, the 5-year DFS of our 21 basal MBC [28] was 89%. Thus, 
our 368-gene classifier identified within basal tumors two subgroups with different 
prognosis. Subgroup 1 was associated with relatively good prognosis, close to that of 
normal-like subtype. 
Because the prognosis of basal breast cancer is usually unfavorable, most 
patients are treated using adjuvant chemotherapy. To determine more precisely the 
link of our predictor with metastatic risk and/or with chemosensitivity, we analyzed 
patients‟ subgroups based upon the systemic treatment they received. A total of 116 
out of the 392 basal breast cancer patients with available follow-up had not received 
any adjuvant chemotherapy and hormonal therapy after surgery. With a median 
follow-up of 102 months, the 5-year DFS was 68% in subgroup 1 and 44% in 
subgroup 2 (p=7E-03, log-rank test). Thirty basal samples were available in the Hess„ 
series treated with primary chemotherapy before surgery, allowing assessment of 
response to chemotherapy. The pathological complete response (pCR) rate was 58% 
in subgroup 1 vs only 17% in subgroup 2 (not significant). Altogether, these 
observations suggested that our genomic predictor is at least associated with 
prognosis in term of relapse risk, whereas its likely association with response to 
chemotherapy needs to be tested in larger series.  
 
Univariate and multivariate analyses 
We performed univariate and multivariate Cox survival analysis in the 
combined data set of 466 basal tumors to compare the prognostic performance of the 
368-gene classifier (subgroups 1 and 2) with that of histoclinical variables. These 
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included age of patients, pathological tumor size, axillary lymph node status, SBR 
grade, and ER, PR, ERBB2, and Ki67 IHC status (Table 3A). In univariate analysis, 
the HR for relapse was 0.53 for subgroup 1 basal tumors compared to subgroup 2 
tumors (95%CI [0.38 – 0.73], p=1.30E-04). Positive lymph node status was 
associated with DFS whereas age, pathological tumor size, grade, and ER, PR 
ERBB2, and Ki67 status were not. 
Multivariate analysis was done on the 343 out of 466 samples with available 
information regarding the two significant variables in univariate analysis (lymph node 
status and 368-gene classifier). Both remained significant (Table 3A), suggesting 
their independent prognostic value. The multigene classifier was the most significant, 
with a HR for relapse of 0.52 for subgroup 1 basal tumors compared to subgroup 2 
tumors (95%CI [0.36 – 0.74], p=3.9E-04), suggesting a higher prognostic value than 
the lymph node status (pN). This gene classifier added prognostic information when 
combined with pN. Indeed, a clinico-genomic model combining pN and the gene 
classifier performed better than pN alone regarding the prediction of DFS (p=1.7E-4 
vs p=9.5E-3 respectively, Wald test). By contrast, predictive performances were very 
close for the clinico-genomic model and the gene classifier alone (p=1.7E-4 vs 
p=1.2E-4 respectively, Wald test). 
 
Comparison of our model with two immune response signatures 
Two prognostic immune signatures have been reported in ER- breast cancer: 
the 7-gene immune response (IR) signature [20,21] and the T-cell metagene [19]. 
Since our model was enriched with immune response genes (see below), we 
evaluated its correlation with these two signatures. No gene overlapped our model 
and the IR signature. Comparison of the classifications of the 466 basal samples 
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based upon our SVM model and the IR signature showed concordance (both 
subgroup 1 and IR good-prognosis, or both subgroup 2 and IR poor-prognosis) for 
only 249 samples (53%). The same analysis was done with the T-cell metagene (50 
genes) and our SVM model, revealing only 2 overlapping genes and 66% of 
concordant classification.  
For further comparison, we repeated the prognostic analysis by incorporating 
the classifications based on these two immune signatures (Table 3B). The 7-gene 
immune response signature was not significant in univariate analysis, whereas the T-
cell metagene was. In multivariate analysis incorporating the three variables 
significant in univariate analysis, the 368-gene classifier was still the strongest 
predictor of DFS, independently of the lymph node status, whereas the T-cell 
metagene lost its prognostic value.  
These observations confirm that our model, which includes immune genes and 
many others, is different from these immune signatures. However, they still highlight 
the role of immunity in the prognosis of basal breast cancer. To try to elucidate the 
type of immune response observed in good-prognosis subgroup 1, we searched for 
correlations between our classification and any of the cell-type specific gene 
expression profiles of leukocytes. Therefore, we determined if the genes that belong 
to publicly available B-cell, T-cell, CD8+ T-cell, lymphocyte, and granulocyte 
signatures [45] were overrepresented in the list of differentially expressed genes 
between subgroup 1 and subgroup 2 using our 75-basal sample IPC data set. Using 
the gene set enrichment analysis (GSEA) algorithm [46] and 1.000 permutations, we 
obtained significance for the B-cell, T-cell, and CD8+ T-cell signatures 
(Supplementary Figure 1). 
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The prognostic impact of the 368-gene classifier is specific to the basal 
subtype 
We investigated whether our 368-gene classifier had a prognostic value in the 
whole population of tumors and in the other subtypes across the “prognostic series” 
of 2034 samples. The results are summarized in Table 4. When tested in the whole 
population (1752 patients with annotated follow-up), the 368-gene classifier did not 
retain any prognostic value. For the analysis per subtype, survival information was 
available in 243 patients with ERBB2 tumor, 578 patients with luminal A tumor, 304 
with luminal B tumor, and 235 with normal-like tumor, with a median follow-up 
ranging from 77 to 95 months according to the subtype. In each non basal subtype, 
survival differences between subgroups 1 and 2 were not significant. These results 
revealed the prognostic specificity of the 368-gene classifier, limited to the basal 
subtype. 
 
Absence of prognostic impact of other prognostic breast cancer 
signatures in the basal subtype 
We assessed the predictive value of six major prognostic expression 
signatures recently reported in early breast cancer. In each data set, each sample 
was assigned a good or a poor prognosis based on each signature. Data sets were 
then pooled and survival was compared between the predicted good-prognosis and 
poor-prognosis subgroups. Results of univariate analysis are shown in Table 4. In the 
whole population, each signature-based classification was strongly associated with 
DFS, further confirming their robustness. However, when the same analysis was 
done per molecular subtype none of the signatures retained any prognostic value in 
the basal tumors, whereas one remained associated with survival in the ERBB2 
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subtype, four in the luminal B and normal-like subtypes, and six in the luminal A 
subtype. These results show the subtype-dependence of these signatures regarding 
their prognostic value, and notably the absence of informative value in the basal 
subtype, by contrast with our classifier.  
 
 
DISCUSSION 
The extent of the differences between the molecular subtypes evidenced by 
high-throughput gene profiling makes it necessary to redefine prognostic and 
predictive markers in each subtype [8]. The interest in such an approach has already 
been evidenced by the fact that several prognostic multigene signatures [12-18] are 
highly informative regarding the prediction of clinical outcome in ER+/ERBB2- tumors, 
but much less in other tumors. Another recent meta-analysis confirmed the interest of 
the analysis per subtype for developing a more accurate prognostic signature [47]. 
The rare studies reported for ER- tumors show the difficulty of identifying prognostic 
multigene signatures in this group [19-22]. This could be because ER- tumors include 
both basal and ERBB2 samples although these two subtypes are different at the 
molecular level. No current signature is associated with basal tumors. To our 
knowledge, the present study is the first one that focuses specifically on basal breast 
cancers. 
We demonstrate that basal breast cancers can be divided into two prognostic 
subgroups based on a 368-gene expression classifier associated with MBC, a rare 
histological type associated with a basal profile but a good prognosis. Subgroup 1 
exhibited greater DFS (71 vs 50%) than subgroup 2, with a HR for relapse was 0.52. 
Although DFS of subgroup 1 remains insufficient - and cannot preclude the use of 
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adjuvant systemic therapy - these differences suggest that subgroup 2 patients 
should need a more aggressive treatment than subgroup 1 patients. Clinico-
pathological differences between both subgroups were slight. Like MBC, subgroup 1 
tumors were more frequently ER- than subgroup 2 tumors. However, they were not 
different with respect to the other histological variables, except for age, younger in 
subgroup 1. This is one of the aims of genomics: to identify molecular subgroups with 
prognostic relevance within tumors similar at the clinico-pathological level but 
different regarding their clinical outcome. Multivariate analysis showed that the 
classifier outperformed the classical histoclinical variables. Its prognostic value was 
specific to basal tumors. By contrast, none of six major prognostic breast cancer 
signatures was associated with DFS in these tumors, whereas all were strongly 
significant in the whole population, and in the luminal A good-prognosis molecular 
subtype. This observation reinforces the value of our 368-gene classifier in the basal 
tumors as well as the interest of the per subtype approach.  
The strength of our results lies also in the original “bottom-up” approach that 
we have applied. Unlike the classical “top-down” supervised approach [48], the 
“bottom-up” approach is based on a starting hypothesis. It consists in first identifying, 
often in a relatively reduced series, a signature associated with a phenotypic feature 
relevant to the relapse process (MBC vs nonMBC here), and then subsequently 
testing for its correlation with outcome in a large and independent series of samples, 
avoiding the problem of overfitting. In the past, prognostic signatures associated with 
wound repair [49], stem cells [18], P53 mutations [16], pathological grade [13], or 
inflammatory breast cancer status [50] have been established this way, thereby 
linking these concepts to tumor cell aggressiveness. Here, we used MBC as a model 
of non-aggressive basal breast cancer, and showed that the associated signature 
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holds the fingerprints of the relative more favorable prognosis of this histological type, 
and that the underlying biological bases are also relevant in basal breast cancers in 
general. 
Since our two basal subgroups were very similar at the clinico-pathological 
level, specific molecular differences should reside in the 368-gene classifier. What 
genes and functions represented in this classifier might be associated with a more or 
less aggressive phenotype is a crucial issue as their identification will help develop 
targeted therapeutic strategies. Ontology analysis revealed several potentially 
interesting pathways. Using the Onto-Express algorithm we had previously shown 
[28] that “Immune response” was the biological process the most represented among 
the 202 signature genes overexpressed in the good-prognosis subgroup 1 tumors, 
followed by processes related to apoptosis, and proteolysis. Even if speculative, it is 
tempting to associate these processes with the better prognosis observed. Ingenuity 
analysis of canonical pathways confirmed these results (Supplementary Table 5). 
Our previous analysis had revealed the implication of TH1 cells in immune response, 
and a likely high global cytotoxic activity. Two Ingenuity pathways were associated 
with IL-15 and IL-12. IL-15 is a critical factor for the proliferation and activation of NK 
and CD8+ T cells. IL-12, and more recently IL-15 and IL-27, demonstrated anti-tumor 
activity in murine models [51]. The presence of NFkB2 and NFkBIE, an inhibitor of 
NFkB, in pathways respectively associated with subgroup 1 and subgroup 2, agrees 
with an activation of the transcriptional machinery of cytotoxic cells in subgroup 1 
[52]. Our GSEA analysis confirmed these results, and also suggested a likely 
involvement of B-cells. The favorable prognostic impact of the immune system has 
been suggested by other studies. In colon cancer, increased levels of mRNA for 
products of TH1 cells are associated with prolonged survival [53]. The four prognostic 
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expression studies dedicated to ER- breast cancers [19-22], as well as a meta-
analysis [10], revealed that immune response favorably impacted the clinical 
outcome. Similar observations were recently reported in highly proliferative tumors 
that included a majority of ER- samples [54]. Our data also agree with the favorable 
contribution of the immune response to response to chemotherapy recently reported 
in breast cancer [19,55,56]. Altogether, these observations suggest a potential 
interest for therapeutic strategies aimed at stimulating the immune defenses in basal 
breast cancer. Despite this enrichment for genes involved in immunity, we showed 
that our model differed from two previously published prognostic immune signatures 
[19-21]. Indeed, beside the immune system, other overrepresented Ingenuity 
pathways involved PKR, PPAR and RXR. PKR is a P53 target protein kinase, which 
plays a crucial role in the tumor-suppressor function of P53 and apoptosis [57]. 
PPARgamma is a ligand-activated transcription factor that regulates cell proliferation 
and differentiation. PPARgamma ligands, through the downregulation of gelatinases, 
inhibit the invasive capacities of breast cancer cells in vitro [58], and repress 
TGFbeta signaling involved in metastasis [59]. Finally, bexarotene (Targretin), an 
RXR (retinoid X receptor) agonist, inhibits angiogenesis and metastasis in vitro after 
activation of its heterodimerization partner PPARgamma [60].  
Regarding the 166 genes overexpressed in the poor-prognosis subgroup 2, 
we had previously identified [28] several Onto-Express biological processes related 
to cytoskeleton, muscle biology, adhesion and tyrosine kinase signaling. Similarly, 
Ingenuity analysis (Supplementary Table 5) identified several pathways related to cell 
migration such as “caveolar-mediated endocytosis”, “virus entry via endocytic 
pathways”, “tight junction signaling”, “agrin interactions at neuromuscular junction”, 
“actin cytoskeleton signaling”, and “clathrin-mediated endocytosis” [61,62]. Indeed, 
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many genes are involved in the architecture and remodeling of cytoskeleton and 
adhesion. Examples include ACTA2, ACTG2, FLNA, FLNC, ACTN1, MYL9, TPM2, 
MYLK, M-RIP, CALD1, CNN2, TAGLN, DAAM1, MTSS1, SMTN, PARVA, FLH1, and 
ADAM12. Other pathways potentially related to tumor aggressiveness included 
“VEGF signaling, “G-protein coupled receptor signaling”, or “NF-kB activation by 
viruses”. Finally, the presence of genes coding for smooth muscle-specific proteins 
(ACTG2, ACTA2, TPM2, MYL9, M-RIP, CALD1, CNN2, SMTN, KCNMB1, TAGLN, 
ACTN1, APEG1, BOC) and of genes upregulated by TGFbeta [63-65] (TAGLN, 
ACTG2, FHL2, TPM2, ACTN1, CNN2, FSTL1, BGN, TGFB1I1) may suggest some 
degree of epithelial-to-mesenchymal transition in the poor-prognosis subgroup, which 
calls for complementary analyses for confirming this hypothesis. . Of note, our 
analysis did not reveal any differential implication of cell cycle and cell proliferation 
pathways, in agreement with the high grade of basal tumors, equally distributed 
between our two prognostic subgroups.  
 
In conclusion, we have shown that early basal breast cancers can be 
classified in two subgroups with different DFS based on a 368-gene model. This new 
prognostic classifier was validated in a series of 466 basal breast cancers and 
outperformed the classical histoclinical features in multivariate analysis. The 
difference for clinical outcome might be due, at least in part, to an effective host 
immune TH1 response, enhanced tumor cell apoptosis, elevated levels of metastasis-
inhibiting factors and low levels of metastasis-promoting factors in the good-
prognosis subgroup, and a more developed cell migration system in the poor-
prognosis subgroup. Clinically, the identification of poor or good prognosis cases 
within basal breast cancers should help select the appropriate systemic treatment, 
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while the identification of biologically relevant genes or pathways included in the 
classifier should provide new potential therapeutical targets. Further validation of our 
model in a larger retrospective series, then in a prospective series is warranted.  
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Table 1. Molecular subtypes and histoclinical correlations 
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Table 2. Histoclinical characteristics of the two basal tumor subgroups 
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Table 3. Univariate and multivariate DFS analyses by Cox regression of 
basal tumors. A/ without, and B/ with the immune response (IR) signature-
based classification. 
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Table 4. Prognostic classification of breast cancers using the 368-gene 
classifier and six prognostic breast cancer signatures.  
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Supplementary Table 1. Description of the breast cancer data sets 
 
Supplementary table 2: IPC data set histoclinical data 
 
Supplementary Table 3. List of 368 genes differentially expressed 
between basal MBC and nonMBC. 
 
Supplementary Table 4: Application of six major prognostic breast 
cancer signatures to our pooled series 
 
Supplementary Table 5. Ingenuity canonical pathways overrepresented 
in the good-prognosis and the poor-prognosis basal breast cancer 
subgroups.  
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 Supplementary Figure 1. GSEA shows correlations between our SVM 
model-based classification of basal breast cancers and cell-type specific gene 
expression signatures of leucocytes. 
A/ Results of GSEA with the five tested signatures. NES, normalized enrichment 
score; FDR, false discovery rate. 
B/ Enrichment plots for the three significant signatures: B-cell, T-cell, and CD8+ T-
cell (from left to right).  
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FIGURE LEGENDS 
 
Fig. 1 Classification of basal MBC and nonMBC based on the 368-gene 
SVM model 
A/ Learning set. SVM model-based classification of 37 IPC basal breast cancers (16 
nonMBC, and 21 MBC) from which we had generated the 368-gene signature and 
defined the SVM model [28]. Top: cross-table. Middle: Box plots of the SVM 
prediction score in MBC and nonMBC samples. The dashed horizontal line indicates 
the threshold 0 that separates two subgroups of samples: subgroup 1 (above the 
line) and subgroup 2 (under the line). Bottom: Classification of samples based on the 
SVM score. The vertical orange line indicates the threshold 0 that separates the two 
subgroups of samples (left of the line, subgroup 1; right to the line, subgroup 2). The 
histological type and the SVM score are color-coded as indicated. B/ Validation set. 
The legend is similar to A, but applies to the validation set (basal samples from [30]). 
 
Fig. 2 Disease-free survival of the two basal breast cancer subgroups 
A/ The 368-gene SVM model was applied to 466 basal breast cancers and defined 
two subgroups 1 and 2. B/ Kaplan-Meier disease-free survival curves of the two basal 
breast cancer subgroups defined in A.  
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Table 2. Histoclinical characteristics of the two basal tumor subgroups  
Characteristics (N) 
Subgroup 1 Subgroup 2 
p-value N=217 N=249 
N (% of evaluated cases) 
Age (378)   4.95E-03 
     ≤ 50 years 115 (65%) 100 (50%)  
     > 50 years 63 (35%) 100 (50%)  
Pathological tumor size pT (370)   0.25 
Table 1: Molecular subtypes and histoclinical correlations    
              
Characteristics (N) 
Basal ERBB2 Luminal A Luminal B Normal-like 
p-value N=466 N=280 N=653 N=359 N=276 
N (% of evaluated cases) 
Age (1661)      3E-05 
     ≤ 50 years 215 (57%) 139 (58%) 231 (43%) 149 (52%) 99 (46%)  
     > 50 years 163 (43%) 99 (42%) 312 (57%) 137 (48%) 117 (54%)  
Histological type (558)      1.46E-02 
     ductal 135 (92%) 49 (92%) 149 (79%) 96 (85%) 41 (72%)  
     lobular 4 (3%) 0 (0%) 17 (9%) 6 (5%) 7 (12%)  
     mixt 3 (2%) 1 (2%) 13 (7%) 6 (5%) 5 (9%)  
     other* 5 (3%) 3 (6%) 9 (5%) 5 (4%) 4 (7%)  
Pathological tumor size pT (1622)      1.00E-05 
     pT1 105 (28%) 90 (38%) 231 (43%) 90 (32%) 98 (49%)  
     pT2-4 265 (72%) 144 (62%) 306 (57%) 190 (68%) 103 (51%)  
Pathological lymph node status pN (1664)      2.77E-03 
     negative 260 (65%) 99 (51%) 346 (62%) 173 (61%) 156 (68%)  
     positive 138 (35%) 96 (49%) 213 (38%) 111 (39%) 72 (32%)  
Tumor grade (1658)      1.00E-05 
     SBR 1 14 (4%) 16 (7%) 148 (28%) 30 (10%) 69 (32%)  
     SBR 2-3 364 (96%) 226 (93%) 389 (72%) 258 (90%) 144 (68%)  
ER IHC status (1923)      1.00E-05 
     negative 340 (78%) 110 (42%) 68 (11%) 25 (7%) 71 (28%)  
     positive 100 (22%) 155 (58%) 556 (89%) 319 (93%) 179 (72%)  
PR IHC status (657)      1.00E-05 
     negative 132 (85%) 47 (64%) 42 (18%) 30 (26%) 28 (33%)  
     positive 24 (15%) 27 (36%) 187 (82%) 84 (74%) 56 (67%)  
ERBB2 IHC status (375)      1.00E-05 
     negative 89 (86%) 14 (40%) 119 (94%) 66 (82%) 26 (84%)  
     positive 14 (14%) 21 (60%) 7 (6%) 14 (18%) 5 (16%)  
P53 IHC status (194)      1.00E-05 
     negative 20 (40%) 4 (27%) 61 (82%) 24 (71%) 16 (76%)  
     positive 30 (60%) 11 (73%) 13 (18%) 10 (29%) 5 (24%)  
KI67 IHC status (202)      1.00E-05 
     negative 5 (8%) 2 (11%) 40 (57%) 5 (14%) 6 (35%)  
     positive 55 (92%) 16 (89%) 30 (43%) 32 (86%) 11 (65%)  
Follow-up, months (1752)      0.1374** 
     median 81 77 89 91 95  
Disease-free survival (1752)      6.91E-13 
     5-year DFS 60% (392) 60% (243) 80% (578) 57% (304) 72% (235)   
N, number of tumor samples - out of the 2034 samples - with available information for the corresponding characteristic  
*, other types include tubular (n=12), metaplastic (n=6), mucinous (n=5), apocrine (n=1), histiocytoid (n=1) and unknown (n=1) 
**, ANOVA test       
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     pT1 44 (25%) 61 (31%)  
     pT2-4 130 (75%) 135 (69%)  
Pathological lymph node status pN (398)   0.25 
     negative 129 (68%) 131 (63%)  
     positive 60 (32%) 78 (37%)  
Tumor grade (378)   0.43 
     SBR 1 5 (3%) 9 (4%)  
     SBR 2-3 172 (97%) 192 (96%)  
ER IHC status (440)   9.14E-04 
     negative 181 (84%) 159 (71%)  
     positive 34 (16%) 66 (29%)  
PR IHC status (156)   0.82 
     negative 77 (86%) 55 (83%)  
     positive 13 (14%) 11 (17%)  
ERBB2 IHC status (103)   1.00 
     negative 58 (87%) 31 (86%)  
     positive 9 (13%) 5 (14%)  
P53 IHC status (50)   0.39 
     negative 13 (46%) 7 (32%)  
     positive 15 (54%) 15 (68%)  
KI67 IHC status (60)   0.19 
     negative 1 (3%) 4 (14%)  
     positive 30 (97%) 25 (86%)  
Follow-up, months (392)   1.18E-02 
     median 94 62  
Disease-free survival (392)   9.93E-05 
     5-year DFS 71% (177) 50% (215)   
 
 
Table 3A: Univariate and multivariate DFS analyses by Cox regression of basal tumors       
                  
 Univariate Analysis  Multivariate Analysis 
  N Hazard Ratio 95% CI p-value   N Hazard Ratio 95% CI p-value 
Age > 50 years (vs ≤ 50 years) 323 1.04 0.73-1.47 0.83      
ER IHC status positive (vs negative) 385 0.75 0.51-1.11 0.15      
PR IHC status positive (vs negative) 106 0.68 0.24-1.97 0.48      
Pathological tumor size pT2-4 (vs pT1) 316 1.38 0.92-2.08 0.12      
Pathological lymph node status positive (vs negative) 343 1.6 1.12-2.28 0.0095  343 1.5 1.05-2.14 0.0271 
ERBB2 IHC status positive (vs negative) 69 1.19 0.28-5.13 0.82      
Tumor grade SBR 2-3 (vs SBR 1) 318 2.04 0.65-6.42 0.22      
KI67 IHC status positive (vs negative) 60 0.46 0.10-2.00 0.30      
SVM classifier-based subgroup 1 (vs sugroup 2) 392 0.53 0.38-0.73 0.000127   343 0.52 0.36-0.74 0.000393 
N is the number of patients with data available regarding the analyzed variables        
          
Table 3B: Similar, but including two immune signature-based classifications (Immune Response IR and T-cell metagene) as additional variables 
                  
 Univariate Analysis  Multivariate Analysis 
  N Hazard Ratio 95% CI p-value   N Hazard Ratio 95% CI p-value 
Age > 50 years (vs ≤ 50 years) 323 1.04 0.73-1.47 0.83      
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ER IHC status positive (vs negative) 385 0.75 0.51-1.11 0.15      
PR IHC status positive (vs negative) 106 0.68 0.24-1.97 0.48      
Pathological tumor size pT2-4 (vs pT1) 316 1.38 0.92-2.08 0.12      
Pathological lymph node status positive (vs negative) 343 1.6 1.12-2.28 0.0095  343 1.56 1.08-2.24 0.0160 
ERBB2 IHC status positive (vs negative) 69 1.19 0.28-5.13 0.82      
Tumor grade SBR 2-3 (vs SBR 1) 318 2.04 0.65-6.42 0.22      
KI67 IHC status positive (vs negative) 60 0.46 0.10-2.00 0.30      
IR signature Good (vs Poor) 392 0.76 0.56-1.04 0.0913      
T-cell metagene Good (vs Poor) 392 0.6 0.43-0.84 0.0031  343 0.75 0.50-1.11 0.15 
SVM classifier-based subgroup 1 (vs sugroup 2) 392 0.53 0.38-0.73 0.000127   343 0.58 0.39-0.85 0.006140 
N is the number of patients with data available regarding the analyzed variables        
 
 
Table 4: Prognostic classification of breast cancers using the 368-gene classifier and six prognostic breast cancer signatures 
           
Pronostic signatures 
All breast cancers Basal   ERBB2   
N  HR* [95% CI]  p-value  N  HR* [95% CI]  p-value  N  HR* [95% CI]  p-value  
MBC signature Subgroup 2  vs 1 1752  1.00 [0.83-1.20] 0.98 392  1.89 [1.37-2.63] 0.00013 243  1.19 [0.73-1.79] 0.4 
70-gene signature Poor  vs Good 1752  2.36 [1.90-2.93] 6.7E-15 392  NaN  NaN 243  1.37 [0.60-3.12] 0.46 
Genomic grade index  Poor  vs Good 1752  2.15 [1.82-2.54] <1E-16 392  0.55 [0.23-1.35] 0.19 243  1.15 [0.71-1.88] 0.57 
76-gene signature  Poor  vs Good 1728  1.78 [1.51-2.09] 2E-12 387  1.37 [0.98-1.92] 0.067 238  1.77 [1.18-2.65] 5.60E-03 
Recurrence score  Intermediate  vs Good 
1752 
 1.76 [1.40-2.21] 1.20E-06 
392 
Inf [0-Inf] 0.99 
243 
 0.63 [0.20-1.97] 0.42 
  Poor  vs Good  2.22 [1.85-2.67] <1E-16 Inf [0-Inf] 0.99  0.97 [0.35-2.63] 0.95 
Wound response signature  Poor  vs Good 1752  1.91 [1.55-2.35] 1.4E-09 392  1.33 [0.19-9.50] 0.78 243  0.94 [0.43-2.02] 0.87 
Invasiveness gene signature  Poor  vs Good 1752  1.64 [1.40-1.91] 6.9E-10 392  0.76 [0.52-1.11] 0.15 243  1.43 [0.88-2.33] 0.15 
           
           
Pronostic signatures 
Luminal A   Luminal B   Normal   
N  HR* [95% CI]  p-value  N  HR* [95% CI]  p-value  N  HR* [95% CI]  p-value  
MBC signature Subgroup 2  vs 1 578  0.89 [0.44-1.82] 0.75 304  0.89 [0.60-1.35] 0.59 235  0.79 [0.25-2.50] 0.7 
70-gene signature Poor  vs Good 578  1.54 [1.11-2.13] 9.50E-03 304  2.98 [1.39-6.36] 4.90E-03 235  2.85 [1.68-4.84] 9.90E-05 
Genomic grade index  Poor  vs Good 578  2.64 [1.85-3.78] 1.10E-07 304  2.21 [1.39-3.52] 7.90E-04 235  3.02 [1.75-5.21] 7.20E-05 
76-gene signature  Poor  vs Good 570  1.44 [1.03-2.00] 3.20E-02 303  1.83 [1.05-3.17] 3.20E-02 230  1.34 [0.82-2.20] 0.24 
Recurrence score  Intermediate  vs Good 
578 
 1.74 [1.19-2.54] 4.00E-03 
304 
 1.16 [0.75-1.77] 0.51 
235 
 2.22 [1.31-3.74] 2.90E-03 
  Poor  vs Good  2.02 [1.16-3.51] 1.30E-02  1.79 [1.21-2.65] 3.50E-03  3.32 [1.88-5.86] 3.30E-05 
Wound response signature  Poor  vs Good 578  1.49 [1.06-2.09] 2.10E-02 304  1.18 [0.52-2.66] 0.7 235  1.97 [1.26-3.08] 3.00E-03 
Invasiveness gene signature  Poor  vs Good 578  1.69 [1.16-2.46] 5.90E-03 304  1.41 [1.00-1.99] 0.052 235  1.45 [0.86-2.46] 0.17 
           
*HR, hazard ratio           
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